Zanubrutinib, Catalog: B2512

IN STOCK!
US$0.00

(7S)-4,5,6,7-Tetrahydro-7-[1-(1-oxo-2-propen-1-yl)-4-piperidinyl]-2-(4-phenoxyphenyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; BGB-3111; (S)-Zanubrutinib; BGB3111

PRODUCT SUMMARY

Alternate Names (7S)-4,5,6,7-Tetrahydro-7-[1-(1-oxo-2-propen-1-yl)-4-piperidinyl]-2-(4-phenoxyphenyl)pyrazolo[1,5-a]pyrimidine-3-carboxamide; BGB-3111; (S)-Zanubrutinib; BGB3111

Appearance White to off-white solid

CAS # 1691249-45-2

Molecular Formula C₂₇H₂₉N₅O₃

Molecular Weight 471.56

Purity ≥ 98% by HPLC

Solubility >50 mg/ml in DMSO

SMILES C=CC(=O)N1CCC(CC1)C2CCNC3=C(C(=NN23)C4=CC=C(C=C4)OC5=CC=CC=C5)C(=O)N

InChi InChI=1S/C27H29N5O3/c1-2-23(33)31-16-13-18(14-17-31)22-12-15-29-27-24(26(28)34)25(30-32(22)27)19-8-10-21(11-9-19)35-20-6-4-3-5-7-20/h2-11,18, 22,29H,1,12-17H2,(H2,28,34)

InChi Key RNOAOAWBMHREKO-UHFFFAOYSA-N

PubChem CID 135905454

Storage Conditions -20ºC

Shipping Conditions Gel Pack

Usage For Research Use Only! Not For Use in Humans.

Handling Do not take it internally. Wear a glove and mask when handling the product. Protect from air and moisture.

DESCRIPTION

Zanubrutinib (BGB3111) is a potent, selective and orally available Btk inhibitor; displaysmuch more restricted off-target activities against a panel of kinases, including ITK, compared with Ibrutinib. BGB-3111 selectively binds to and inhibits the activity of BTK and prevents the activation of the B-cell antigen receptor (BCR) signaling pathway.